Redeye revisits its view of Orexo as the company announced the positive results from its first explorative human clinical phase I trial with OX640. The initial results are promising for the continued clinical development and commercialization of OX640, we believe several catalysts related to the project are to be expected in the coming 12-24 months. We adjust our base case to reflect the inclusion of OX640 in our valuation.